EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database

Xinkuo Zheng, Meishen Liu, Aili Ding, Shihong Zhang, Ling Wu, Fanli Kong, Weijia Sun, Yuchen Peng, Yalin Xi

Frontiers in Cellular and Infection Microbiology · 2025

DOI: 10.3389/fcimb.2025.1635180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Xinkuo Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Central Hospital of Dalian University of Technology, Dalian, China. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Pharmacovigilance, Product Surveillance, Postmarketing, Adverse Drug Reaction Reporting Systems. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pneumococcal vaccines have been utilized in the United States for decades with extensive clinical safety records. However, comprehensive post-marketing pharmacovigilance evaluations for all available types remain lacking. This study aimed to assess adverse events following immunization (AEFI) using the VAERS database and analyze potential associations between adverse events (AEs) and vaccine administration based on VAERS data.

Methods

We retrieved all AEs associated with pneumococcal vaccines recorded in the VAERS database from 1990 through March 2025. Descriptive analyses were conducted to summarize the demographics, clinical characteristics, and vaccination profiles of reported cases. Disproportionality analysis was performed to detect potential safety signals between AEs and vaccine administration.

Results

The VAERS database documented 157,244 individuals receiving pneumococcal vaccines, with 158,778 doses administered, capturing 632,481 AE reports following vaccination during the study period. Females showed higher AE reporting rates (54.29%) compared to males (36.88%), with the majority of cases (38.20%) occurring in individuals aged < 18 years. Complete recovery (44.20%) and hospitalization (14.94%) were the most common outcomes. Most AEs (77.11%) occurred within 0–30 days post-vaccination (median onset: 0 day). Pneumococcal polysaccharide vaccine (PPSV, 48.92%) and 13-valent pneumococcal conjugate vaccine (PCV13, 27.57%) constituted the predominant vaccine types. Disproportionality analysis identified 929 positive AE signals across 24 system organ classes (SOCs), with injection site erythema [reporting odds ratio (ROR) = 4.24], injection site swelling (ROR = 4.19), and injection site pain (ROR = 2.75) being the most frequent. Designated Medical Event (DME) screening revealed erythema multiforme (n = 398) and product contamination microbial (ROR = 11.25) as key safety signals. General disorders (ROR = 1.73) and skin conditions (ROR = 1.69) were the predominant SOC categories.

Conclusions

This post-marketing surveillance has revealed predominantly non-serious AEs, with most adverse events clustered within 30 days post-vaccination. These observations reinforce the established safety profile of pneumococcal vaccines while emphasizing temporal risk patterns to guide post-vaccination monitoring protocols and risk-benefit evaluations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumococcal VaccinesPharmacovigilanceProduct Surveillance, PostmarketingAdverse Drug Reaction Reporting SystemsPneumococcal InfectionsDrug-Related Side Effects and Adverse ReactionsHumansFemaleMaleMiddle AgedAgedUnited StatesAdultAdolescentYoung AdultChild, PreschoolChildInfantDatabases, FactualAged, 80 and overVaccination

Stichwörter der Autor:innen

adverse eventspharmacovigilancepneumococcal vaccinespost-marketing safety surveillancesafetyvaccine adverse event reporting system

Substanzen

Pneumococcal Vaccines

Autor:innen und Institutionen

  • Department of Pharmacy, Central Hospital of Dalian University of Technology, Dalian, China.
  • Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.

Zitieren

APA

Zheng, X., Liu, M., Ding, A., Zhang, S., Wu, L., Kong, F., Sun, W., Peng, Y., & Xi, Y. (2025). Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1635180

Vancouver

Zheng X, Liu M, Ding A, Zhang S, Wu L, Kong F, et al. Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1635180

BibTeX
@article{Zheng2025,
  author = {Zheng, Xinkuo and Liu, Meishen and Ding, Aili and Zhang, Shihong and Wu, Ling and Kong, Fanli and Sun, Weijia and Peng, Yuchen and Xi, Yalin},
  title = {Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1635180}
}
Kostenlos starten →